4th Palermo Conference on INNOVATIVE THERAPIES FOR LYMPHOID MALIGNANCIES
Haematologica, Vol 92, Issue 2, 285-286 doi:10.3324/haematol.10358
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Remacha, A. F.
Right arrow Articles by Fontcuberta, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Remacha, A. F.
Right arrow Articles by Fontcuberta, J.

Thrombosis

The V617F mutation of JAK2 is very uncommon in patients with thrombosis

Angel F. Remacha, Camino Estivill, M. Pilar Sarda, José Mateo, Joan Carles Souto, Carme Canals, Josep Nomdedéu, Jordi Fontcuberta

Department of Hematology, Hospital de Sant Pau, Avda Padre Claret 167, Barcelona 08025, Spain

Correspondence: Angel F. Remacha, Department of Hematology, Hospital de Sant Pau, Avda Padre Claret 167, Barcelona 08025, Spain. Phone: international +34.9.32919290. Fax: international +34.9.32919192. E-mail: aremacha{at}hsp.santpau.es

Given that many cases of thrombosis do not have a clear cause, a myeloproliferative disease could be involved. We investigated the V617F mutation of the JAK2 gene in 295 patients with thrombosis. Only one case was positive. Therefore, the study of this mutation is not necessary in all patients with idiopathic thrombosis.

Key words: JAK2 mutation, idiopathic thrombosis.




This article has been cited by other articles:


Home page
 BloodHome page
F. Dentali, A. Squizzato, L. Brivio, L. Appio, L. Campiotti, M. Crowther, A. M. Grandi, and W. Ageno
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
Blood, May 28, 2009; 113(22): 5617 - 5623.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
P. M. Mannucci and F. Peyvandi
Thrombophilia Screening: Little Role for the JAK2V617F Mutation
Mayo Clin. Proc., April 1, 2008; 83(4): 398 - 399.
[Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
A. Pardanani, T. L. Lasho, K. Hussein, S. M. Schwager, C. M. Finke, R. K. Pruthi, and A. Tefferi
JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive Patients
Mayo Clin. Proc., April 1, 2008; 83(4): 457 - 459.
[Abstract] [Full Text] [PDF]